Medicine tube for needle-free injection and needle-free injection including the medicine tube
By designing a spray hole diameter of less than or equal to 0.12 mm and a stagnation pressure of 10MPa to 26MPa in a needle-free syringe, the stability and universality of existing needle-free syringes in intradermal injection is solved, and efficient skin-based Intra-injection effect.
Patent Information
- Application Number
- CN202311535622.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-16
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2043-11-16
AI Technical Summary
When the existing needle-free syringe is injected intradermal injection, the diameter of the spray hole is between 0.16 mm and 0.2 mm, and it is not stable to achieve intradermal injection, and it is not universal, resulting in difficulty in injection and pain problems.
A medicine tube for needle-free syringe is designed, with the diameter of the spray hole less than or equal to 0.12mm. By controlling the diameter of the spray hole and the stagnation pressure of the medicine liquid between 10MPa and 26MPa, the lateral diffusion of the medicine liquid is achieved to ensure that Stable intradermal injection.
Stable intradermal injection within the range of 0.12 mm orifice diameter and 10 MPa to 26 MPa stagnation pressure was achieved, improving the reliability and universality of the injection, with the injection completion rate reaching 85% to 98%.
Smart Images

Figure CN117504053B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of medical devices, and in particular to a medicine tube for a needle-free syringe and a needle-free syringe comprising the medicine tube. Background Art
[0002] Intradermal injection is the injection of drugs into the epidermis and dermis of the skin, but not into the subcutaneous tissue. Intradermal injection is often used for drug tests to prevent allergies (such as penicillin skin test), preparations before local anesthesia in surgery (such as procaine skin test), and vaccinations (such as BCG). In addition, intradermal injection can reduce the amount of vaccine used and increase vaccine utilization.
[0003] Usually, a needle syringe or a needle-free syringe is used for intradermal injection. However, there are problems of difficult operation and injection pain in needle-free intradermal injection. The diameter of the nozzle of the existing needle-free syringe is between 0.16 mm and 0.2 mm. For example, when using an existing needle-free syringe with pneumatic power source for intradermal injection, the liquid pressure (i.e., stagnation pressure) of the medicine inside the medicine tube can be adjusted by changing the gas pressure (i.e., injection pressure) provided by the air pressure device. However, in the case where the diameter of the nozzle of the needle-free syringe is between 0.16 mm and 0.2 mm, it is impossible to stably achieve intradermal injection by adjusting the stagnation pressure inside the medicine tube. In addition, other operations that can stably achieve intradermal injection can also be used, for example, changing the injection distance (i.e., the distance between the nozzle of the needle-free syringe and the skin) by using spacers of different thicknesses, but these other operations cannot be universally applied to all needle-free syringes, and therefore have low universality.
[0004] The above description of the background technology is only for facilitating an in-depth understanding of the technical solution of the present invention (such as the technical means used, the technical problems solved and the technical effects produced), and should not be regarded as an admission or any form of implication that the information constitutes prior art already known to those skilled in the art. Summary of the invention
[0005] An object of the present invention is to provide a drug cartridge for a needle-free injector and a needle-free injector including the drug cartridge, which can achieve stable intradermal injection.
[0006] According to one embodiment of the present invention, there is provided a medicine barrel for a needle-free syringe, wherein the needle-free syringe ejects a target injection liquid from the ejection port into the epidermis and dermis of the skin in a state where the ejection port is in contact with the surface of the skin, and the medicine barrel comprises: a housing portion having a housing space for accommodating the target injection liquid; a nozzle portion, which is fluidically connected to the housing portion and is provided with the ejection port, and guides the target injection liquid accommodated in the housing portion to the ejection port; wherein the diameter of the ejection port is less than or equal to 0.12 mm.
[0007] Preferably, the diameter of the ejection port is less than or equal to 0.1 mm.
[0008] Preferably, when the ejection port is formed by laser drilling, the diameter of the ejection port is between 0.05 mm and 0.1 mm, and when the ejection port is formed by injection molding, the diameter of the ejection port is between 0.08 mm and 0.1 mm.
[0009] Preferably, when the diameter of the ejection port is less than or equal to 0.12 mm, the target injection liquid in the containing space is pressurized to between 10 MPa and 26 MPa during the entire injection process.
[0010] Preferably, when the diameter of the ejection port is less than or equal to 0.1 mm, the target injection liquid in the containing space is pressurized to between 16 MPa and 26 MPa during the entire injection process.
[0011] Preferably, when the diameter of the ejection port is between 0.05 mm and 0.1 mm or between 0.08 mm and 0.1 mm, the target injection liquid in the containing space is pressurized to between 16 MPa and 25 MPa during the entire injection process.
[0012] Preferably, the target injection liquid diffuses laterally within the epidermis and dermis of the skin.
[0013] According to another embodiment of the present invention, a needle-free syringe is provided, comprising: a medicine tube, which is the above-mentioned medicine tube for needle-free syringes; a driving portion, which imparts injection energy for ejecting the target injection liquid; and a propulsion body, which moves in a predetermined direction inside the containing portion by being imparted with the injection energy, thereby pressurizing the target injection liquid contained in the containing space.
[0014] The needle-free syringe includes: a medicine core barrel, which has a first accommodating chamber extending along its own length direction as the accommodating part and an injection head connected to the front end of the first accommodating chamber as the nozzle part, the inner wall of the front part of the first accommodating chamber forms a retracted part extending radially inward; a push rod, which serves as the propulsion body and is endowed with the injection energy and can be slidably arranged in the first accommodating chamber; a self-destructive plug, the rear end of the self-destructive plug is connected to the front end of the push rod, and under the push of the push rod, the outer peripheral surface of the self-destructive plug contacts the inner peripheral surface of the retracted part, and the friction between the outer peripheral surface of the self-destructive plug and the inner peripheral surface of the retracted part is greater than the friction between the self-destructive plug and the push rod.
[0015] The needle-free syringe includes: a medicine core barrel, which has a first accommodating chamber extending along its own length direction as the accommodating portion; an injection head, which serves as the nozzle portion, is connected to the front end of the medicine core barrel and is fluidically connected to the first accommodating chamber; a push rod, which serves as the propulsion body and is endowed with the injection energy and can be slidably arranged in the first accommodating chamber; a first injection one-way device, which is arranged in the first accommodating chamber and is used to allow the target injection liquid in the first accommodating chamber to flow toward the injection head; a drug feeding device, which is connected to the medicine core barrel and is fluidically connected to the first accommodating chamber; a second injection one-way device, which is arranged in the drug feeding device and is used to allow the target injection liquid in the drug feeding device to flow to the first accommodating chamber.
[0016] The present invention adopts the above technical scheme, which has the following beneficial effects: According to the embodiment of the present invention, by controlling the injection parameters of the medicine tube of the needle-free syringe, the lateral diffusion of the drug solution in the skin can be achieved. Specifically, the diameter of the spray hole of the injection medicine tube is controlled within 0.12mm, and the stagnation pressure (i.e., the drug liquid strength) inside the medicine tube is within 10MPa to 26MPa. The use of these injection parameters is beneficial to the stable injection in the skin. In addition, the spray hole of the injection medicine tube can be formed by laser drilling or by injection molding. It is suitable for the formation of micropores of different sizes, has a reasonable design, and can be promoted on a large scale. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] The following will describe the exemplary embodiments of the present invention in more detail with reference to the accompanying drawings. For the sake of clarity, the same components in different drawings are shown with the same reference numerals. It should be noted that the drawings are only for illustration and are not necessarily drawn to scale. In these drawings:
[0018] Figure 1 Schematic diagram of the structure of a needle-free syringe according to one embodiment of the present invention.
[0019] Figure 2 A schematic structural diagram of a needle-free syringe according to another embodiment of the present invention is shown.
[0020] Figure 3 Shows Figure 1 The push rod 12 is endowed with a structure of ejection energy by high pressure gas.
[0021] Figure 4A and Figure 4B are respectively corresponding to Figure 1 and Figure 2 Schematic diagram of the structure of the injection head of the needle-free syringe. DETAILED DESCRIPTION
[0022] The implementation scheme of the present invention is described in detail below. This implementation scheme is implemented on the premise of the technical scheme of the present invention, and a detailed implementation method and specific operation process are given, but the protection scope of the present invention is not limited to the implementation scheme described below.
[0023] Intradermal injection refers to injecting the target injection liquid only into the intradermal space of the individual (i.e., the epidermis and dermis of the skin). "Individual" can be a human, and can also include vertebrates, but are not limited to farm or production animals (such as pigs, cattle, poultry, horses), pets, primates, mice and rats. Throughout the specification, the process and results of the experiment on rats are described. The sum of the thickness of the epidermis and dermis of rat skin is in the range of 1mm to 1.9mm. For the thickness of the epidermis and dermis of human skin, the cheek area is the thinnest, with the sum of the thickness of the epidermis and dermis being 1mm, and the inner area of the upper arm is the thickest, with the sum of the thickness of the epidermis and dermis being 2mm. Since the sum of the thickness of the epidermis and dermis of rat skin is close to the sum of the thickness of the epidermis and dermis of human skin, the experiment on rats can show the experimental effect when the needle-free syringe injects a specific target injection liquid only into the intradermal space of the subject similar to human skin.
[0024] The diameter of the spray hole of the existing needle-free syringe is between 0.16 mm and 0.2 mm. It is impossible to stably achieve intradermal injection by adjusting the stagnation pressure inside the medicine tube or changing the injection distance and other operations, and the universality is not high.
[0025] For example, the three existing needle-free syringes are a 0-1 ml miniaturized low-pressure needle-free syringe (hereinafter referred to as a "gun-type GV-1 syringe"), an INJEX 3.0 syringe, and a QuickShure QS-P syringe.
[0026] Table 1 shows the specifications of three existing needle-free syringes.
[0027] Table 1
[0028]
[0029]
[0030] As shown in Table 1, the diameters of the nozzle holes of the three needle-free syringes are all 0.16 mm.
[0031] Intradermal injections were tested using the three needle-free syringes.
[0032] Specifically, the needleless syringe can be equipped with a vial needle and 0.1 ml of methylene blue solution can be drawn. Next, the rat is placed on a tray and the hair on the back is shaved to expose the skin for intradermal injection. The methylene blue solution, as an indicator or dye, can help the operator observe the changes in the shape and color of the rat's skin after intradermal injection.
[0033] The pneumatic gun-type GV-1 syringe can adjust the injection pressure and the spacer distance. The injection pressure is the gas pressure provided by the pneumatic device. The spacer is a device that is arranged on the nozzle and matched with the nozzle, and is used to press against the skin to change the injection distance. The spacer distance (i.e., the injection distance) refers to the distance between the nozzle and the skin. The methylene blue solution was injected into the rat using the gun-type GV-1 syringe, and the injection situation (specifically, whether it is exudation or leakage) was observed. In addition, the injection completion rate parameter can be further used to quantify the leakage situation. Among them, the injection completion rate represents the ratio of the dose injected into the recipient to the injection dose, and the dose injected into the recipient is determined by weighing the amount of liquid medicine remaining outside. After the injection is completed, the size of the skin papule is measured, and then the dissection is photographed to observe the layer of the liquid medicine (specifically, whether it is intradermal or subcutaneous) and record it. After re-adjusting at least one of the injection pressure, the spacer distance and the impact spacing, the above steps are repeated. Thus, the test results in Table 2 can be obtained.
[0034] Table 2
[0035]
[0036]
[0037] According to Table 2, when 0.1 ml of methylene blue solution was injected into rats' skin by the gun-type GV-1 syringe by adjusting the injection pressure or the spacer distance, the injection leaked or penetrated through the skin to the subcutaneous layer in most cases.
[0038] The INJEX3.0 syringe with a spring as the power source does not need to adjust the injection pressure. The INJEX3.0 syringe is not equipped with a spacer. The INJEX3.0 syringe is used to inject 0.1 ml of methylene blue solution into rats, and two sets of data are recorded. Thus, the test results in Table 3 can be obtained.
[0039] Table 3
[0040]
[0041] According to Table 3, when 0.1 ml of methylene blue solution was injected into the rat skin with the INJEX syringe, a skin mound could be formed, but in most cases the injection passed through the skin to the subcutaneous layer and the leakage amount exceeded half.
[0042] The QS-P syringe does not need to be pre-adjusted. The QS-P syringe was used to inject 0.1 ml of methylene blue solution into the rats, and two sets of data were recorded. Thus, the test results in Table 4 can be obtained.
[0043] Table 4
[0044]
[0045] According to Table 4, when the QS-P syringe injected 0.1 ml of methylene blue solution into the rat's skin, the injection force (i.e., the mechanical energy storage of the spring) of the QS-P syringe was too large, and the methylene blue solution was injected through the skin to the subcutaneous layer. The injection completion rate was high, but the skin papule formed was small and did not meet the requirements for intradermal injection.
[0046] When a needle-free syringe is used for injection, there is a situation where part of the liquid medicine can be injected into the skin or subcutaneously and part of the liquid leaks at the same time. For example, it can be seen from the test results of Tables 2 to 4 that when the methylene blue solution is injected into the skin or subcutaneously, leakage occurs at the same time. This is because the injection force in the early stage can meet the injection requirements. As the amount of injected liquid increases and the internal pressure at the injection site increases, the subsequent injection force is not enough to inject all the liquid medicine into the target site, resulting in leakage. The effect of intradermal injection can be reflected by the injection level and the injection completion rate. For example, the higher the injection level is intradermal and the higher the injection completion rate, the better the intradermal injection effect. However, when the injection level is subcutaneous, no matter how high the injection completion rate is, it cannot indicate the effect of intradermal injection.
[0047] Stable intradermal injection is extremely important for needle-free injection. It is difficult for existing needle-free syringes to achieve reliable and stable intradermal injection for different people (or animals) and different parts of the same patient. In order to solve this problem, the present invention provides a needle-free syringe, which can eject the target injection liquid from the ejection port into the epidermis and dermis of the skin in a state where the ejection port is in contact with the surface of the skin. The needle-free syringe of the present invention may include a housing, a nozzle, a driving part and a propulsion body. The housing has a storage space for accommodating the target injection liquid. The nozzle is in fluid communication with the housing and is provided with an ejection port, and guides the target injection liquid contained in the housing to the ejection port. The driving part imparts ejection energy for ejecting the target injection liquid. The propulsion body moves in a predetermined direction inside the housing by being endowed with the ejection energy, thereby pressurizing the target injection liquid contained in the housing space.
[0048] Figure 1 Schematic diagram of the structure of a needle-free syringe according to one embodiment of the present invention. Figure 1 As shown, the needle-free syringe includes a core barrel 11 and a push rod 12. In addition, Figure 1 The needle-free syringe shown is a single-use needle-free syringe and includes a self-destructive plug 16 .
[0049] Specifically, the core barrel 11 can serve as the above-mentioned accommodating portion and nozzle portion. The core barrel 11 has a first accommodating chamber 13 (i.e., the accommodating portion) extending along its own length direction and an injection head 14 (i.e., the nozzle portion) connected to the front end of the first accommodating chamber 13. The inner wall of the front part of the first accommodating chamber 13 forms a retracted portion 15 extending radially inward. The first accommodating chamber 13 and the injection head 14 contain the target injection liquid. The injection head 14 is provided with a spray hole, i.e., the above-mentioned ejection port. The above-mentioned propulsion body is constructed in the shape of a rod extending along the length direction of the first accommodating chamber 13. The push rod 12 as a propulsion body can be slidably arranged in the first accommodating chamber 13. Preferably, a sealing ring 17 is arranged between the push rod 12 and the inner surface of the first accommodating chamber 13.
[0050] The rear end of the self-destruct plug 16 is connected to the front end of the push rod 12. Under the push of the push rod 12, the outer peripheral surface of the self-destruct plug 16 contacts the inner peripheral surface of the indentation 15, and the friction between the outer peripheral surface of the self-destruct plug 16 and the inner peripheral surface of the indentation 15 is greater than the friction between the self-destruct plug 16 and the push rod 12.
[0051] Therefore, when the push rod 12 drives the self-destruct plug 16 to push toward the front end of the first accommodating chamber 13 to inject liquid to the injection target, the self-destruct plug 16 moves to the injection head 14 of the core barrel 11. If the user wants to use it again and pulls the push rod 12, the friction between the outer circumference of the self-destruct plug 16 and the inner circumference of the retracted portion 15 is greater than the friction between the self-destruct plug 16 and the push rod 12, and the self-destruct plug 16 will separate from the push rod 12, and then the self-destruct plug 16 will stay in the injection head 14, so that the injection device cannot be used again.
[0052] The needle-free injection device may further include a Luer connector 18. During pre-filling, the Luer connector 18 may be used to install a rubber sleeve, which isolates the drug core cartridge 11 from the outside world.
[0053] Figure 2 FIG. 2 shows a schematic diagram of the structure of a needle-free syringe according to another embodiment of the present invention. Figure 2 As shown, the needle-free syringe includes an injection head 24 , a core barrel 21 and a push rod 22 . Figure 2 The needle-free injector shown is a continuous-use needle-free injector and includes a first injection one-way device 23 , a second injection one-way device 25 and a drug-injecting device 27 .
[0054] The medicine core barrel 21 has a first accommodating chamber 26 extending along its own length direction as the above-mentioned accommodating portion. The injection head (i.e., the nozzle portion) 24 is connected to the front end of the medicine core barrel 21 and is fluidically connected to the first accommodating chamber 26. Therefore, during multiple injections, the injection head 24 can be disassembled and replaced. A spray hole (i.e., an ejection port) is provided on the injection head 14. A push rod (i.e., a propulsion body) 22 is slidably arranged in the medicine core barrel 21. The first injection one-way device 23 is arranged in the first accommodating chamber 26, and is used to allow the target injection liquid in the first accommodating chamber 26 to flow toward the injection head 24. The drug feeding device 27 is connected to the medicine core barrel 11 and is fluidically connected to the first accommodating chamber 26. The second injection one-way device 25 is arranged in the drug feeding device 27, and is used to allow the target injection liquid in the drug feeding device 27 to flow to the first accommodating chamber 26.
[0055] Therefore, continuous injection can be achieved through the reciprocating motion of the push rod 22. When the push rod 22 moves forward, the target injection liquid can be ejected from the injection head 24. When the push rod 22 is pulled back, negative pressure is formed in the first accommodating chamber 26, and the target injection liquid in the drug feeding device 27 is drawn into the first accommodating chamber 26, thereby achieving continuous injection.
[0056] In one embodiment of the present invention, the driving unit can use high pressure gas as the injection energy. Figure 1 As an example, Figure 3 Shows Figure 1 The push rod 12 is endowed with a structure of ejection energy by high pressure gas.
[0057] like Figure 3 As shown, the through hole 39 of the handle portion 38 is connected to high-pressure gas (i.e., compressed gas), so that the high-pressure gas enters the air inlet chamber 40 of the handle portion 38. The high-pressure gas in the air inlet chamber 40 is divided into two paths, the first path bypasses the outer peripheral surface of the bracket 41 and enters the front chamber 31A, and the second path can enter the rear chamber 31B through the first channel 42, the trigger chamber 43, and the second channel 44. At this time, both the front chamber 31A and the rear chamber 31B have high-pressure gas, so that the air pressure on both sides of the balance valve 32 is the same.
[0058] Under the action of the elastic force provided by the elastic member 33, the balancing valve 32 contacts the sleeve 34 to continue to block the second accommodating chamber 35. When the trigger 45 is pulled, the trigger 45 pushes the valve stem 36 to move backward, so that the valve stem 36 blocks the trigger chamber 43. The high-pressure gas in the air intake chamber 40 can no longer pass through the first channel 42, the trigger chamber 43 and the second channel 44 to enter the rear chamber 31B. At this time, the rear chamber 31B can no longer obtain high-pressure gas. However, the front chamber 31A can still continue to obtain high-pressure gas, so that the air pressure of the front chamber 31A is greater than the air pressure of the rear chamber 31B, so as to push the balancing valve 32 to move backward while overcoming the elastic member 33.
[0059] After the balancing valve 32 moves backward, the balancing valve 32 no longer blocks the second accommodating chamber 35, so that the second accommodating chamber 35 is connected to the front chamber 31A, and the high-pressure gas in the front chamber 31A enters the second accommodating chamber 35. The high-pressure gas entering the second accommodating chamber 35 pushes the piston 46 and the striker 37 to move forward, so as to push the push rod 12 to move forward. The target injection liquid contained in the core barrel 11 is pressurized and ejected from the nozzle of the injection head 14 to complete the injection.
[0060] However, the present invention does not limit the structure of the needle-free syringe. That is, the structure of the needle-free syringe is not limited to the above two embodiments. Specifically, the accommodating portion is not limited to the shape of a cylinder. The propulsion body is not limited to the shape of a rod. The propulsion body can also be a film that expands in a specific direction, a fold that stretches along a given specific direction, etc. The driving portion is also not limited to using high-pressure gas as the injection energy. The driving portion can also use the electrical energy of a piezoelectric element, etc., the mechanical energy of a spring, etc. as the injection energy, or can generate the injection energy by appropriately combining these forms of energy.
[0061] According to an embodiment of the present invention, the diameter of the ejection port is less than or equal to 0.12 mm, and the target injection liquid in the accommodation space is pressurized to an appropriate range (e.g., between 10 MPa and 26 MPa), that is, the stagnation pressure in the accommodation space is between 10 MPa and 26 MPa, so as to achieve stable injection of the target injection liquid into the epidermis and dermis of the skin. In addition, the target injection liquid can diffuse laterally in the epidermis and dermis of the skin.
[0062] Specifically, Figure 4A and Figure 4B are respectively corresponding to Figure 1 and Figure 2 Schematic diagram of the structure of the injection head of the needle-free syringe. Figure 4A and Figure 4B As shown, the diameter D (i.e., the ejection port) of the nozzle opening on the injection head 14, 24 is less than or equal to 0.12 mm. Figure 1 and Figure 3 By connecting the high-pressure gas to move the push rods 12 and 22, the target injection liquid in the core tubes 11 and 21 is pressurized to between 10 MPa and 26 MPa. Figure 1 and Figure 2 The needle-free injection device shown can stably inject the target injection liquid into the epidermis and dermis of the skin.
[0063] The test of intradermal injection was carried out using a needle-free syringe according to various embodiments of the present invention. Similarly, 0.1 ml of methylene blue solution was extracted. Then, the rat was placed on a tray and the hair on the back was shaved to expose the skin to be intradermally injected. The methylene blue solution was injected into the rat using a needle-free syringe according to various embodiments of the present invention, and the injection was observed. After the injection, the size of the papule was measured, and then the dissection was taken and photographed, and the layers of the liquid were observed and recorded. Subsequently, another needle-free syringe was replaced so that the ejection port of the needle-free syringe was changed within a range of less than or equal to 0.12 mm or the stagnation pressure inside the needle-free syringe was changed within a range of 10 MPa to 26 MPa, and the above steps were repeated. Thus, the test results of Table 5 can be obtained.
[0064] Table 5
[0065]
[0066]
[0067] As shown in Table 5, the injection levels are all intradermal, and the injection completion rate is in a very high range (i.e., approximately in the range of 85% to 98%). It can be concluded that a needle-free syringe with an ejection port diameter less than or equal to 0.12 mm and a stagnation pressure between 10 MPa and 26 MPa can achieve reliable and stable intradermal injections.
[0068] The diameter of the spray hole of the existing needle-free syringe is greater than or equal to 0.16 mm. According to the embodiment of the present invention, the diameter of the spray hole of the needle-free syringe is set to be less than or equal to 0.12 mm. The smaller the diameter of the spray hole, the more conducive it is to intradermal injection. However, the diameter cannot be infinitely small. If the diameter of the spray hole is too small, the injection time will be prolonged and it will be easily blocked by suspended matter in the target injection liquid (such as vaccine) during injection, which is not conducive to the stability of injection. On this basis, the stagnation pressure inside the medicine tube is further controlled within an appropriate range (i.e., between 10MPa and 26MPa), so that reliable and stable intradermal injection can be achieved.
[0069] In a preferred embodiment, when the diameter of the ejection port is less than or equal to 0.1 mm, the target injection liquid in the containing space is pressurized to between 16 MPa and 26 MPa during the entire injection process. The corresponding test results are shown in Table 6.
[0070] Table 6
[0071]
[0072] As shown in Table 6, the injection levels are all intradermal. In addition, compared with the injection completion rate shown in Table 5, the injection completion rate shown in Table 6 is further improved, that is, the injection completion rate is approximately in the range of 92% to 98%.
[0073] According to the above test results, the core diameter less than or equal to 0.12mm is conducive to forming a stable intradermal injection, and the smaller the diameter, the more conducive to forming a stable intradermal injection. However, due to the limitation of the process, the diameter cannot be infinitely small. At present, the suitable range of the diameter produced by the injection production process is 0.08mm to 0.12mm. If it is less than 0.08mm, the production qualification rate is very low. Considering the conditions of injection stability, the diameter produced by the injection molding process has a better solution of 0.08mm to 0.1mm for stable intradermal injection. The minimum diameter produced by the laser drilling production process can reach 0.01mm, but considering the structural strength and the problem of easy blockage during the injection process (that is, too small an aperture will prolong the injection time and it is easy to be blocked by suspended matter in the vaccine during injection), the diameter produced by the laser drilling production process has a better solution of 0.05mm to 0.1mm for stable intradermal injection.
[0074] Therefore, in another preferred embodiment, when the ejection port is formed by laser drilling, the diameter of the ejection port is between 0.05 mm and 0.1 mm, and when the ejection port is formed by injection molding, the diameter of the ejection port is between 0.08 mm and 0.1 mm. When the diameter of the ejection port is between 0.05 mm and 0.1 mm or between 0.08 mm and 0.1 mm, the target injection liquid in the containing space is pressurized to between 16 MPa and 25 MPa during the entire injection process. The corresponding test results are shown in Table 7.
[0075] Table 7
[0076]
[0077]
[0078] As shown in Table 7, the injection levels are all intradermal. In addition, compared with the injection completion rate shown in Table 5, the injection completion rate shown in Table 7 is further improved, that is, the injection completion rate is approximately in the range of 92% to 99%.
[0079] According to the embodiment of the present invention, by controlling the injection parameters of the drug tube of the needle-free injector, the lateral diffusion of the drug solution in the skin can be achieved. Specifically, the diameter of the spray hole of the injection drug tube is controlled within 0.12 mm. The smaller the diameter of the spray hole, the more conducive it is to form intradermal injection, and the stagnation pressure (i.e., the drug liquid pressure) inside the drug tube is within an appropriate range (e.g., 10 MPa to 26 MPa). The use of these injection parameters is beneficial to the stable injection in the skin.
[0080] In addition, the spray hole of the injection tube can be formed by laser drilling or injection molding. It is suitable for forming micropores of different sizes, has a reasonable design, and can be promoted on a large scale.
[0081] The various embodiments of the invention are not an exhaustive list of all possible combinations, but are intended to describe representative aspects of the invention, and what is described in various embodiments may be applied independently or in combinations of two or more.
[0082] The description presented in the above exemplary embodiments is only used to illustrate the technical solution of the present invention, and is not intended to be exhaustive, nor is it intended to limit the present invention to the precise form described. Obviously, it is possible for a person of ordinary skill in the art to make many changes and variations based on the above teachings. The exemplary embodiments are selected and described to explain the specific principles of the present invention and its practical application, so that other technicians in the field can easily understand, implement and use the various exemplary embodiments of the present invention and its various selected forms and modified forms. The scope of protection of the present invention is intended to be limited by the attached claims and their equivalent forms.
Claims
1. A medicine tube for a needle-free syringe, wherein the needle-free syringe ejects a target injection liquid from the ejection port into the epidermis and dermis of the skin in a state where the ejection port is in contact with the surface of the skin, the medicine tube comprising: a containing portion having a containing space for containing the target injection liquid; a nozzle portion, which is in fluid communication with the receiving portion and is provided with the ejection port, and guides the target injection liquid received in the receiving portion to the ejection port; Wherein, the diameter of the ejection port is less than or equal to 0.12 mm; Wherein, when the ejection port is formed by laser drilling, the diameter of the ejection port is between 0.05 mm and 0.1 mm, and when the ejection port is formed by injection molding, the diameter of the ejection port is between 0.08 mm and 0.1 mm; wherein, during the entire injection process, a stagnation pressure is applied to the target injection liquid in the containing space, wherein the stagnation pressure remains unchanged during the entire injection process, and the stagnation pressure is a pressure between 10 MPa and 26 MPa; Wherein, the target injection liquid diffuses laterally in the epidermis and dermis of the skin.
2. The drug cartridge for a needle-free injector according to claim 1, wherein: The stagnation pressure is a pressure between 16 MPa and 25 MPa.
3. A needle-free syringe, comprising: A medicine tube, which is a medicine tube for a needle-free injector according to claim 2; a driving unit that imparts ejection energy for ejecting the target injection liquid; The propelling body is provided with the ejection energy and moves in a predetermined direction inside the accommodation portion, thereby pressurizing the target injection liquid accommodated in the accommodation space.
4. The needle-free injector according to claim 3, wherein: The needle-free syringe comprises: The core barrel has a first accommodating cavity extending along its length direction as the accommodating portion and an injection head connected to the front end of the first accommodating cavity as the nozzle portion, wherein the inner wall of the front portion of the first accommodating cavity forms a retracted portion extending radially inwards; A push rod, which serves as the propulsion body and is endowed with the ejection energy and is slidably disposed in the first accommodating cavity; A self-destructive plug, the rear end of which is connected to the front end of a push rod. Under the push of the push rod, the outer circumference of the self-destructive plug contacts the inner circumference of the indentation, and the friction between the outer circumference of the self-destructive plug and the inner circumference of the indentation is greater than the friction between the self-destructive plug and the push rod.
5. The needle-free injector according to claim 3, wherein: The needle-free syringe comprises: The drug core tube has a first accommodating cavity extending along its length direction as the accommodating portion; An injection head, which serves as the nozzle portion, is connected to the front end of the medicine core barrel and is in fluid communication with the first accommodating chamber; A push rod, which serves as the propulsion body and is endowed with the ejection energy and is slidably disposed in the first accommodating cavity; A first injection one-way device, which is disposed in the first accommodating chamber and is used to allow the target injection liquid in the first accommodating chamber to flow toward the injection head; A drug feeding device, which is connected to the drug core barrel and is in fluid communication with the first accommodating chamber; The second injection one-way device is arranged in the drug feeding device and is used to allow the target injection liquid in the drug feeding device to flow to the first accommodating chamber.
Citation Information
Patent Citations
Injection device
CN116407709A
Device assembly for needleless syringe
CN116437974A
Non needle head injection syringe for animals
CN201105061Y
Injection device with re-usable pressure generating means
US20040055662A1
